These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 302552)

  • 21. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay.
    Greenberg AH; Shen L; Medley G
    Immunology; 1975 Oct; 29(4):719-29. PubMed ID: 810417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct subsets of accessory cells activate Thy-1+ triple negative (CD3-, CD4-, CD8-) cells and Th-1 delayed-type hypersensitivity effector T cells.
    Matsushima GK; Stohlman SA
    J Immunol; 1991 May; 146(10):3322-31. PubMed ID: 1673982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell contact-mediated macrophage activation for antileishmanial defense. II. Identification of effector cell phenotype and genetic restriction.
    Sypek JP; Panosian CB; Wyler DJ
    J Immunol; 1984 Dec; 133(6):3351-7. PubMed ID: 6333458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation between cytotoxic lymphocytes and cells that synthesize the macrophage migration inhibitory factor in the H-2 system].
    Suslov AP; Egorova SG; Brondz BD
    Biull Eksp Biol Med; 1975 Oct; 80(10):86-90. PubMed ID: 776251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Thymus target cells subject to the regulatory effect of macrophages during the formation of graft-versus-host reaction effectors].
    Galaktionov VG; Anfalova TV; Lutsan NI
    Biull Eksp Biol Med; 1983 Jul; 96(7):79-81. PubMed ID: 6603240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage requirements of CR- and CR+ B lymphocytes for antibody production in vitro.
    Hoffmann MK; Hämmerling U; Simon M; Oettgen HF
    J Immunol; 1976 May; 116(5):1447-51. PubMed ID: 1083874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymocyte and macrophage interactions: separation of murine thymocyte subsets and enrichment of syngeneic cell-responding thymocytes by adsorption to macrophage monolayers.
    Wu S; Thomas DW
    J Immunol; 1983 Nov; 131(5):2110-6. PubMed ID: 6226732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
    Evans R; Duffy T
    J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response of BALB/c X DBA/2F1 mice to a tumor allograft during pyran copolymer-induced tumor enhancement.
    Schultz RM; Woods WA; Mohr SJ; Chirigos MA
    Cancer Res; 1976 May; 36(5):1641-6. PubMed ID: 1268825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human lymphocyte cytotoxicity against mumps virus-infected target cells. Requirement for non-T cells.
    Härfast B; Andersson T; Perlmann P
    J Immunol; 1975 Jun; 114(6):1820-3. PubMed ID: 1168673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells.
    Williams RM; Germain RN; Benacerraf B
    J Natl Cancer Inst; 1975 Mar; 54(3):697-708. PubMed ID: 1091740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction and properties of cytotoxic T cells specific for hapten-coupled tumor cells.
    Dennert G; Hatlen LE
    J Immunol; 1975 Jun; 114(6):1705-12. PubMed ID: 805174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro studies of the rabbit immune system. VI. Rabbit anti-mouse cytotoxic T effector cells are inhibited by anti-rabbit T cell serum in the absence of complement.
    Redelman D; Trefts PE
    J Immunol; 1978 Oct; 121(4):1532-9. PubMed ID: 308967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional heterogeneity of helper T cells: two distinct helper T cells are required for the production of T cell growth factor.
    Larsson EL
    J Immunol; 1982 Feb; 128(2):742-5. PubMed ID: 6798123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC; Rodrigues D
    J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies to T cells in patients with systemic lupus erythematosus can induce antibody-dependent cell-mediated cytotoxicity against human T cells.
    Kumagai S; Steinberg AD; Green I
    J Clin Invest; 1981 Mar; 67(3):605-14. PubMed ID: 6970750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement.
    Lustig HJ; Bianco C
    J Immunol; 1976 Jan; 116(1):253-60. PubMed ID: 1245741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Ia antigen expression in macrophages derived from bone marrow cells cultured in granulocyte-macrophage colony-stimulating factor or macrophage colony-stimulating factor.
    Falk LA; Wahl LM; Vogel SN
    J Immunol; 1988 Apr; 140(8):2652-60. PubMed ID: 3128601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.